Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Philips Foundation 2022 Annual Report: partnering to provide healthcare access to over 26 million people in underserved communities 15-05-2023, 21:00

Synchronoss and Verizon Sign Cloud Contract Extension through 2030 19-07-2023, 19:00